Drugmaker GSK said its RSV vaccine gave long-term protection in older adults after a single shot, according to results from its late stage clinical trial.
Wednesday its RSV vaccine gave long-term protection in older adults after a single shot, according to results from its late stage clinical trial, promising news for efforts to combat the common and potentially lethal infection.GSK said the shot, which is designed to protect adults ages 60 and older and is marketed as Arexvy, conveyed strong protection against lower respiratory tract disease and severe disease from RSV over two full seasons.
The findings, which have yet to be fully published, come from the company’s late stage trial of around 25,000 people testing the safety and efficacy of a single dose of Arexvy against RSV, a very common respiratory infection that normally only causes mild, cold-like illness in healthy adults but can trigger severe, possibly fatal, disease in older adults, young infants and those with underlying health conditions.
Lasting protection was also observed in people with underlying health conditions or of advanced age, GSK said, a particularly important finding given the vulnerability of these groups following infection. Tony Wood, GSK’s chief scientific officer, said the result “reinforces our confidence in [the vaccine’s] potential to make a significant public health impact.”
Other data, notably the shot’s safety and ability to provoke an immune response, were consistent with earlier observations from the trial, which showed the shot to be safe and have side effects in line with other vaccines.It’s not clear how often people will need to be vaccinated against RSV and the seasonal nature of the virus—similar to what happens with flu—suggests vaccines could be yearly.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
CDC advisory panel backs use of GSK and Pfizer RSV vaccines in adults 60 and olderThe CDC panel's recommendation moves the U.S. closer to making the respiratory syncytial virus shots from Pfizer and GSK available to seniors.
Read more »
US CDC advisers recommend older adults may receive Pfizer, GSK shots for RSVA panel of advisers to the U.S. Centers for Disease Control and Prevention (CDC) on Wednesday recommended that new vaccines from Pfizer and GSK to prevent severe respiratory syncytial virus (RSV) infections be available to older adults in the U.S. but stopped short of saying all of them should get the shots.
Read more »
Pfizer RSV vaccine for older adults is only slightly less effective after 18 monthsPfizer will present the RSV vaccine results to a CDC advisory committee, which will decide when and how often the shot should be administered in the U.S.
Read more »
Pfizer RSV vaccine for older adults is slightly less effective after 18 monthsPfizer will present the RSV vaccine results to a CDC advisory committee, which will decide when and how often the shot should be administered in the U.S.
Read more »
Next Vaccine You Should Get? Health Advisers May Recommend RSV ShotsGSK and Pfizer RSV vaccines were approved earlier this year by the FDA for adults aged 60 and older.
Read more »
CDC advisers vote to recommend first RSV vaccines for seniorsThe first vaccines to guard against the respiratory illness RSV, respiratory syncytial virus, could soon be available for older adults, ages 60 and over.
Read more »